Your cart is currently empty!
Decitamyl (Decitabine) Injection
Generic brands for Decitabine Injection Available in India Brand Name Decitamyl Generic Name Decitabine Strength 30mg, 50mg Manufacturer Celon Laboratories Ltd
Description
Description
This page contains brief details about the drug decitabine, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Decitabine is a prescription drug that belongs to the class of medication called DNA methylation inhibitors approved for its medical use on February 02, 2006.
Mechanism of Action of Decitabine
Decitabine promotes hypomethylation of DNA and cellular differentiation or cell death after phosphorylation, direct incorporation into DNA, and inhibition of DNA methyltransferase. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
Uses of Decitabine
It is used to treat myelodysplastic syndrome (a group of conditions in which the bone marrow produces blood cells that are misshapen and do not produce enough healthy blood cells). It is also used to treat a type of cancer called acute myeloid leukemia (AML). It works by stopping the cancer cells from growing.
Decitabine Dosage available
The drug is available as a injection in two doses 30mg and 50mg. It will be given to you by a doctor or nurse in a hospital or clinic setting trained in cancer chemotherapy. It is given as an intravenous infusion drip (into your vein). This will take one hour. Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors.
We can ship to :
News/Updates
References
- Dacogen 50 mg powder for concentrate for solution for infusion – Summary of Product Characteristics (SmPC) – (emc). www.medicines.org.uk. [Revised February 2022]. [Accessed April 21, 2023.] https://www.medicines.org.uk/emc/product/2838/smpc
- Highlights of prescribing information – decitabine; [Revised on 2013]. [Accessed April 21, 2023.] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205582s000lbl.pdf
- Issa JP. Decitabine. Current Opinion in Oncology. [revised 2003 Nov] [cited 2020 Jan 2];15(6):446–51. Available from: https://pubmed.ncbi.nlm.nih.gov/14624227/